Repaglinide
USP/1600813 - United States Pharmacopeia (USP) Reference Standard
Synonym: (S)
CAS Number: 135062-02-1
Empirical Formula (Hill Notation): C27H36N2O4
Molecular Weight: 452.59
MDL Number: MFCD00906179
Linear Formula: C27H36N2O4
Product Type: Chemical
| API family | repaglinide |
| application(s) | pharmaceutical (small molecule) |
| format | neat |
| grade | pharmaceutical primary standard |
| InChI | 1S/C27H36N2O4/c1-4-33-25- |
| InChI key | FAEKWTJYAYMJKF-QHCPKHFHSA |
| manufacturer/tradename | USP |
| SMILES string | CCOc1cc(CC(=O)N[C@@H](CC( |
| Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
| Biochem/physiol Actions: | Repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. |
| Biochem/physiol Actions: | Repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. It represents a new class of insulin secretagogues, structurally unrelated to sulphonylureas, which were developed for the treatment of type 2 diabetes. |
| General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia ![]() |
| Other Notes: | Sales restrictions may apply. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41116107 |

